CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Incanthera PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Incanthera PLC
76 King Street
Phone: +44 1618175005p:+44 1618175005 MANCHESTER, M2 4NH  United Kingdom Ticker: INCINC
Business Summary
Incanthera plc is a United Kingdom-based dermatology and oncology therapeutics company. The Company is focused on drug discovery and the development of targeted medicines for the treatment of cancer. Its lead product is Sol, a topical product developed for the treatment of solar keratosis and the prevention of skin cancers. Its pipeline of drug candidates includes Sol, EP0015, Equin and Duo-C. EP0015 targets the treatment of adult solid cancers remains palliative rather than curative and represents an unmet need. Equin is a quinone-based prodrug activated by the enzyme DT-diaphorase, which itself is over-expressed in many solid tumors, including breast, colon, liver, bladder, stomach, central nervous system, lung tumors and melanomas. Duo-C focuses on targeting colorectal cancer using duocarmycins, which are recognized for their extreme cytotoxicity, converted to a prodrug and designed to overcome their intrinsic toxicity and make them manageable and useful in the clinical setup.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20233/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman TimothyMccarthy 66 10/23/2017 10/23/2017
Chief Executive Officer, Director Simon J.Ward 10/23/2017 10/23/2017
Chief Financial Officer LauraBrogden
Head of Communications and Company Secretary SuzanneBrocks 1/1/2022 1/1/2022
Senior Independent Non-executive Director CarolineMurray 2/23/2022 2/23/2022

General Information
Number of Employees: 8 (As of 3/31/2023)
Outstanding Shares: 77,824,166 (As of 9/30/2023)
Stock Exchange: AQS


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024